2016 Continuous Manufacturing Conference - ISPE

Continuous Manufacturing in the News

12 April 2016:  With the launch of the FDA's recently-released draft guidance, Advancement of Emerging Technology Applications to Modernize the Pharmaceutical Manufacturing Base, continuous manufacturing is generating headlines as big pharmaceutical companies take on the task of transiting from batch processing to a more reliable continuous manufacturing model.  Here from the FDA on how they're supporting this transition and how Janssen Products, a Johnson & Johnson company, received the first FDA approval to change their production method.

Attend these presentations at the ISPE Continuous Manufacturing Conference to hear from companies who are currently in operation and/or development phases of a continuous manufacturing model:

  • Johnson & Johnson – Business Case Drivers and Deployment Strategies in the Current Landscape for Continuous Drug Product Manufacturing
    10:30 - 11:00, Wednesday, 20 April
  • Eli Lilly & Co. – Utilization of Online Chromatography Platforms in Drug Substance Continuous Processing: From Process Development to Manufacturing
    11:30 - 12:00, Wednesday, 20 April
  • Vertex – Continuous Manufacturing: Experiences Since Launch
    17:15 - 17:45, Wednesday, 20 April

View Education Program »

This conference is supported by the following ISPE Communities of Practice:

  • Process Analytical Technology & Lifecycle Control Strategy
  • Oral Solid Dosage
  • Biotechnology

We are honored to have a speaker from one of the category winners of the 2016 Facility of the Year Awards (FOYA).

Discounted rates apply for groups of 3 or more!

 Add to your Calendar »Register Now »

Click here for Attendee Only access to:

Conference Presentations »

Please note - the following presentations are not available per presenter determination: Dolores Hernán, Christopher Hwang, Vidya Swaminathan, Kelly Swinney

Attendee Roster »

Read more about Continuous Manufacturing in:
The Link

View the Brochure

Hear from Global Regulators!

Dolores Hernán Pérez de la Ossa, PhD

Quality Specialist / Human Medicines Evaluation Division, EMA, United Kingdom

Rapti Madurawe, PhD

Division Director (Acting), Office of Process and Facilities, FDA/CDER/OPQ

David Doleski

Deputy Director (Acting), Office of Process and Facilities, FDA/CDER/OPQ

Kurt Brorson, PhD

Lab Chief (Acting), Office of Biotechnology Products, FDA/CDER/OPQ